Smart blood pressure cuffs could protect cancer patients from heart risks
NCT ID NCT07592481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether a connected blood pressure monitor, supervised daily by a healthcare assistant, helps patients with blood cancers like CLL or lymphoma stick to home monitoring. The goal is to catch and manage high blood pressure early, a common side effect of BTK inhibitor drugs. Forty adults starting these drugs will use the device for 6 months, and researchers will track how often they take readings and how satisfied they are with the system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- connected home blood pressure monitoring device
- What this could lead to
- If successful, this approach could improve early detection and management of high blood pressure caused by BTK inhibitors, potentially reducing heart-related side effects.
- What could go wrong
- This is a small pilot study with only 40 participants, so results may not apply to everyone. It focuses on adherence to monitoring, not on whether it actually prevents complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Smartwatches track hidden heart risk in blood cancer patients
- Triple-Drug attack aims to outsmart mantle cell lymphoma